Free Priority Shipping on USA orders over $150 – 24‑hr processing – Live phone support
Free Priority Shipping on USA orders over $150 – 24‑hr processing – Live phone support
Original price was: $45.00.$39.95Current price is: $39.95.
The BPC-157 + TB-500 blend is a synthetic peptide combination engineered for controlled laboratory and in vitro research applications. It pairs a gastric pentadecapeptide analogue (BPC-157) with a thymosin beta-4–derived fragment (TB-500) to support investigations into cellular repair, tissue dynamics, and peptide interactions under defined experimental conditions.
Peak Science Peptides supplies this blend as a lyophilized powder to optimize stability, storage, and reconstitution flexibility for research workflows. All peptides offered are pharmaceutical grade and accompanied by third‑party laboratory testing to verify identity, purity, and lot-specific quality. This product is intended for research purposes only and is not approved for therapeutic or diagnostic use.
BPC-157 (Body Protection Compound‑157) is a 15‑amino‑acid peptide originally characterized as a gastric juice–derived fragment and widely studied in preclinical models of tissue protection and repair. TB-500 is a synthetic analogue of thymosin beta‑4, a naturally occurring protein implicated in cell migration, actin regulation, angiogenesis, and wound‑healing pathways.
In a combined format, the BPC-157 + TB-500 blend allows researchers to explore complementary mechanisms of local tissue modulation and systemic cell‑migration signaling in a single standardized reagent. This makes the blend suitable for experimental designs that examine matrix remodeling, cytokine environments, angiogenic responses, and structural recovery processes in vitro or in appropriate model systems.
Peak Science Peptides focuses on providing research‑only peptides with consistent, lot‑tracked quality and transparent analytical documentation. Each batch of BPC-157 + TB-500 is supported by independent third‑party testing to confirm peptide identity, purity, and contaminant thresholds before release.
By combining pharmaceutical‑grade synthesis with external lab verification, this product is designed to help laboratories reduce variability, improve reproducibility, and generate more reliable data when studying peptide-mediated pathways. Researchers can integrate the blend into existing assay platforms, pilot experiments, or comparative analyses alongside single‑agent peptide controls.
Published and commercial research materials indicate that this blend is often used to study tendon, ligament, muscle, vascular, and epithelial responses, especially in models of injury, inflammation, or structural remodeling. Laboratories may employ the blend in cell‑based assays, biochemical stability studies, and mechanistic investigations of peptide synergy and receptor-level signaling. These applications remain preclinical, with no approved therapeutic indications for the combination.
No. Current literature and regulatory statements indicate that neither BPC-157 nor TB-500 has formal approval as a therapeutic drug for any indication in major regulatory jurisdictions. Existing data are predominantly derived from animal models, in vitro work, and early‑stage investigations, and comprehensive human clinical trials are limited. For this reason, the blend is sold strictly as a research peptide and is not intended for diagnostic, therapeutic, or other clinical applications.
Comparable BPC-157 + TB-500 research products on the market typically undergo high‑performance liquid chromatography (HPLC) and mass spectrometry testing to confirm purity levels often reported above 99%. Independent third‑party laboratories also verify identity and check for residual solvents, impurities, and degradation products as part of standard peptide quality control. Peak Science Peptides follows this pharmaceutical‑grade, third‑party tested model to support consistent performance in research protocols.
Reviews and expert commentary note that while preclinical studies frequently report favorable tolerability, robust long‑term safety data in humans for BPC-157, TB-500, and their combination are lacking. TB-500’s influence on cell migration has prompted theoretical discussion about its use in contexts involving abnormal cell growth, emphasizing the need for careful risk assessment in experimental design. As with all unapproved research peptides, the blend should only be used within appropriate laboratory frameworks that adhere to institutional, ethical, and regulatory guidelines.
Reviews
There are no reviews yet.